Metabolic syndrome (MS) is a cluster of different diseases, namely central obesity, hypertension, hyperglycemia, and dyslipidemia, together with a pro-thrombotic and pro-inflammatory state. These metabolic abnormalities are often associated with an increased risk for cardiovascular disease (CVD) and cancer. Dietary and lifestyle modifications are currently believed more effective than pharmacological therapies in the management of MS patients. Nevertheless, the relatively low grade of compliance of patients to these recommendations, as well as the failure of current therapies, highlights the need for the discovery of new pharmacological and nutraceutic approaches. A deeper knowledge of the patho-physiological events that initiate and support the MS is mandatory. Lipid-sensing nuclear receptors (NRs) are the master transcriptional regulators of lipid and carbohydrate metabolism and inflammatory responses, thus standing as suitable targets. This review focuses on the physiological relevance of the NRs (peroxisome proliferatoractivated receptors, liver X receptors, and farnesoid X receptor) in the control of whole-body homeostasis, with a special emphasis on lipid and glucose metabolism, and on the relationships between metabolic unbalances, systemic inflammation, and the onset of CVD. Future perspectives and possible clinical applications are also presented.  /sysbio resistance but respond to thiazolidinediones. J Clin Invest 2003, 112:608-618. 138. Koutnikova H, Cock TA, Watanabe M, Houten SM, Champy MF, Dierich A, Auwerx J. Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPAR gamma hypomorphic mice.
INTRODUCTION

Metabolic Syndrome
M etabolic Syndrome (MS) is a cluster of clinical disorders including central obesity, hypertension, hyperinsulinemia and insulin resistance (leading to impaired fasting glycemia and glucose tolerance and to type 2 diabetes), atherogenic dyslipidemia [low levels of high-density lipoprotein cholesterol (HDL-c), high levels of triglycerides (TG), and low-density lipoprotein (LDL) particles], inflammation, and a pro-thrombotic state. 1, 2 When clustered together, these clinical conditions may amplify or confer additive risk for the development of cardiovascular disease (CVD). Over the past decade, several classification systems have been proposed to describe the clinical features of MS. 1, [3] [4] [5] [6] The National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATPIII) 1 is currently accepted as the most accurate definition in terms of sensitivity and specificity. Although the etiology of MS is still unknown, there is consensus that both genetic background and unhealthy lifestyle habits (insufficient physical exercise and calorie overload) contribute coordinately to the onset of MS, resulting in an increased risk for CVD, cancer, and thrombosis. 2 There is a general agreement that lifestyle modifications may have the potential to more effectively ameliorate most of the clinical features of MS. Nevertheless, several pharmacological approaches, including thiazolidinediones (TDZ), cannabinoid CB1 receptor antagonists, ezetimibe, and fibrates, have been extensively used. There is an increasing interest in elucidating the metabolic pathways underlying the maintenance of energy homeostasis and, in this regard, nuclear receptors (NRs) and their role in the metabolic homeostasis have received great attention over the past decade. The purpose of this review is to provide insights into the metabolic pathways governed by lipid-sensing NRs, and endorse them as feasible and promising therapeutic targets in the management of MS.
Nuclear Receptors
NRs are key players in the coordination of the development, metabolism, circadian rhythms, cell growth, and differentiation. NRs are transcription factors transducing different signals into modulation of gene transcription, 7 thus participating in the control of all complex processes in living organisms. NRs show considerable specificity in their activation and tissue-specific expression, 8 and they can work as monomers, homodimers, and heterodimers. 7 In the human genome 48 NRs have been identified, whereas in rodents there are 49. 7 NRs are called 'orphans' when the endogenous ligands are unknown, 9, 10 and 'true orphans' when NRs regulate the transcription independent of binding to specific ligands. 11, 12 Some NRs are regulated by small lipophilic ligands [i.e., hormones, vitamins, dietary lipids, bile acids (BAs), xenobiotics, etc.]. 9, 12, 13 In this review, we focus on the 'adopted orphan' lipid sensors, namely the peroxisome proliferator-activated receptors (PPARs), the liver X receptors (LXRs), and the farnesoid X receptor (FXR), which all form heterodimers with the retinoid X receptors (RXR). NRs are characterized by a conserved modular structure including an amino-terminal ligand-independent activation function domain (AF-1), a DNA-binding domain (DBD), and a region involved in protein-protein interaction and transcriptional activation of target-gene expression. The DBD is composed of two zinc-finger motifs, which bind a specific hormone response element (HRE). 14, 15 HREs contain the canonical sequence AGGTCA that can be present alone or repeated. Thus, HREs can differ in terms of extension, duplications, and orientation of the repeats (direct, inverted, or everted) 7 ; as a consequence, HREs can be selective for a given NR or for a class of receptors. The ligand-binding domain (LBD) contains a ligand-dependent activation function-2 (AF-2) motif that mediates coactivator recruitment. 13 In the absence of ligand, the LBD of many NRs is bound to transcriptional corepressor complexes that cause chromatin condensation and gene silencing. Ligand binding to NRs induces a change in NR three-dimensional conformation, which results in the dissociation of corepressors and in a subsequent recruitment of tissue-specific coregulators (allowing a fine-tuning of the physiologic response to ligand binding) and transcription machineries. 7, 11, 12 PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS Peroxisome proliferator-activated receptors are ligand-inducible transcription factors acting as 'fatty acid sensors' to control metabolic programs and to regulate energy homeostasis. 16 PPARs form obligate heterodimers with RXRs and bind to specific consensus DNA sites termed PPAR response elements (PPREs). PPREs are composed of direct repeats (DRs) of hexameric sequences AGGTCA, interspaced only by a single nucleotide spacer (DR-1 motif), located in the promoter/enhancer region of target genes. X-ray crystal analyses revealed that, compared with other NRs, the PPAR ligand-binding pocket is unusually large (about 1300Å) and can accommodate a wide diversity of natural and synthetic compounds, including native and modified (oxidized and nitrated) fatty acids (FA), eicosanoids, derivatives of polyunsaturated FA, fibrates, and TDZ. [17] [18] [19] [20] [21] [22] [23] Three PPAR isotypes exist in mammals: PPARα (NR1C1), PPARβ/δ (NR1C2), and PPARγ (NR1C3). Although the three PPAR subtypes share a high degree of sequence and structure homology, they are characterized by a very specific tissue distribution and unique physiological functions. 24 In the following paragraphs, we focus on the physiological functions of PPAR subtypes with a special emphasis on those related to the key features of MS (i.e., elevated TG, low HDL-c, and glucose imbalance).
PPARα
In the late 1960s peroxisome proliferation and hepatomegaly were first reported occurring in rat livers when treated with clofibrate or related compounds (termed peroxisome proliferators) and, several years later (1990), the first receptor for these molecules was cloned and named PPARα. 25 PPARα acts as master transcriptional regulator of FA utilization and is prominently expressed in the liver and, to a lesser extent, in kidney, heart, skeletal muscle, small intestine, brown adipose tissue (BAT), immune cells, and endothelium. 26, 27 Fibrates bind to PPARα in the high micromolar range (that may explain why large doses are required for clinical use) and to a lesser extent to PPARγ and PPARβ/δ contributing to some of the metabolic effects. Given the ability of PPARα agonists to modulate both TG and HDL metabolism, 28, 29 fibrates are currently used for the management of primary hypertriglyceridemia, combined hyperlipidemia, type 3 dyslipoproteinemia, and lipid abnormalities associated with type 2 diabetes and MS. 30
PPARα and Triglyceride Metabolism
The major physiological function of PPARα is to promote FA utilization, and the first PPRE has been identified in the 5 -flanking sequence of the rat acyl-CoA oxidase (ACOX) gene. 31 PPARα target genes are involved in FA transport and uptake [FA transport protein (FATP), CD36, and carnitine-palmitoyltransferase 1 (CPT-1)] and β-oxidation (ACOX, thiolase, acyl-CoA-dehydrogenase, cytochrome P450ω-hydroxylase), and their transcriptional activation contributes to FA homeostasis in lipid-metabolizing tissues such as liver, heart, and muscle ( Figure 1 ). 32-36 Accordingly, PPARα knockout animals exhibited fatty liver phenotype (steatosis), peripheral tissue lipid accumulation, adipocytes hypertrophy, and late onset obesity (despite a stable caloric intake). 37-39 Several proteins involved in the apolipoprotein (apo) B-containing lipoprotein metabolism, such as lipoprotein lipase (LPL), apoCIII, apoAV, and proprotein convertase subtilisin/type 9 (PCSK9) are PPARα target genes. [40] [41] [42] [43] [44] [45] The well-documented TG-lowering properties of PPARα agonists result from both an increased lipolysis and clearance of TG-rich lipoproteins (via activation of LPL and inhibition of apoCIII) and a reduced availability of free FA (FFAs) for TG synthesis (via enhanced β-oxidation). PPARα activation influences the circulating levels of apoB100containing lipoproteins (via increased VLDL-apoB100 catabolism), as well as their distribution profile (via lower levels of small dense LDL and higher concentrations of large buoyant LDL), although the outcomes are not fully elucidated. 46, 47 
PPARα and HDL Metabolism
PPARα agonists modulate the plasma levels of HDL-c through an increased HDL production rate, higher apoAI mRNA levels, stimulation of ATP-binding cassette transporter A1 (ABCA1)-mediated cholesterol efflux in macrophages, and reduced cholesteryl ester transfer protein (CETP) levels. 30 Endothelium FIGURE 1 | Schematic representation of peroxisome proliferator-activated receptor (PPAR)α transcriptional activation (left): as a heterodimer of retinoid X receptors (RXR), PPARα binds the PPAR response elements (PPREs), containing direct repeats (DR) of hexameric sequences AGGTCA, interspaced only by a single nucleotide spacer (DR-1). Effects of PPARα activation in tissues involved in metabolic homeostasis (right): PPARα reduces plasma triglycerides (TG) by inducing fatty acid (FA) transport and oxidation in liver, adipose tissue, and muscle. In addition, PPARα induces lipolysis in adipocytes and hepatocytes. PPARα also modulates lipoprotein metabolism both in the liver, where PPARα induces ApoAI expression and clearance of TG-rich lipoproteins, and in macrophages, where PPARα promotes the efflux of cholesterol, the uptake of oxidized LDL, and the expression of lipoprotein lipase (LPL), thus promoting lipoprotein remodeling. In the endothelium, PPARα exerts athero-protective properties, inhibiting the release of adhesion molecules and inflammatory cytokines, while enhancing vascular remodeling. that can promote the athero-protective process of the reverse cholesterol transport (RCT).
PPARα Clinical Usefulness
Although fibrates, both in monotherapy and in combination with statins (HMG-CoA-reductase inhibitors) or ezetimibe (cholesterol absorption inhibitor), are effective on both TG and HDL metabolism, 51-54 the currently available fibrates are weak ligands for PPARα and there is a quest for both highly selective PPARα agonists and SPPARMs (selective PPAR modulators). Nissen et al. provided the first description of the beneficial effects of a powerful (3000 times more potent than fenofibrate) and highly selective PPARα agonist (LY518674) that, when given to patients with hypercholesterolemia, lowered plasma TG and raised HDL-c and LDL-c. 55 More recently, LY518674 was given to subjects with MS for 8 weeks; along with a 23% reduction in plasma TG and no change in HDL concentration, LY compound was able to increase both apoAI and apoAII production rate by 31 and 71%, respectively, as well as the fractional catabolic rate of these two apolipoproteins. 56 Recently, Chakravarthy et al. identified a new endogenous ligand of PPARα, the phospholipid (PL) palmitoyl-2-oleoyl-sn-glycerol-3phosphocholine (16:0/18:1-GPC), that exhibited a weak activation on PPARβ/δ but not on PPARγ in vitro. This ligand seems to be indispensable for hepatic PPARα activation and its function during fasting. 57 The clinical relevance of fibrate use in type 2 diabetes and MS is still under debate and requires further investigations. Although in clinical trials involving type 2 diabetes patients, such as Diabetes Atherosclerosis Intervention Study (DAIS) and Fenofibrate Intervention and Event Lowering in Diabetes (FIELD), fenofibrate appeared effective on the progression of diabetes-related microvascular disease, it is not clear whether fibrates alone may efficiently impact the lipid abnormalities associated with MS, or if a combination with other lipidlowering drugs, such as statins or insulin-sensitizing agent metformin, should be always recommended in the management of the cardiovascular risk. 58 Future insights may come from ongoing trials such as Action to Control Cardiovascular Risk in Diabetes Trial or studies aiming to test more selective PPARα agonists in both in vitro and in animal models. From a translational point of view, a comment has to be made on the existence of species differences (mostly rodent vs human), 59,60 in apolipoprotein, 61 and glucose metabolism. 62, 63 The difference is also evident in terms of carcinogenesis since a mouse-specific cancer susceptibility profile of PPARα activation is completely absent in the humanized model. 64 At present, the mechanisms responsible for PPARα species differences are not fully elucidated; however, it has been suggested that they may be due to differences in the level of PPARα expression or in the functional DNA-binding capacity or in PPREs found upstream of critical target genes. 59
PPARβ/δ
Since its cloning in 1992, 65,66 PPARβ/δ has been the focus of far less research, compared with PPARα and PPARγ . 67 PPARβ/δ exhibits a broad expression pattern but is more abundantly expressed in lipidmetabolizing tissues such as skeletal muscle, heart, small intestine, and adipose tissue. 68 PPARβ/δ has a short N-terminal domain in which no bona fide ligandindependent activation domain has been identified so far, although a modulation of PPARβ/δ activity by cAMP-dependent phosphorylation may occur via this domain. 69 Among the PPAR subtypes, PPAR β/δ pocket is the smallest one and features a convoluted space where the hydrocarbon tail of unsaturated FA binds. 70 Polyunsaturated FA [eicosapentaenoic acid (EPA), arachidonic acid (ARA), and dihomoγ -linoleic acid], prostaglandin A1, E2, and D2 bind to PPARβ/δ at low concentrations (micromolar range), whereas only prostacyclin (PGI) and its stable analog (carba-prostacyclin) activate PPARβ/δmediated transcription in a nanomolar range of concentrations. 71 Selective synthetic PPARβ/δ agonists have been recently developed (GW501516, GW0742), displaying both in vitro and in vivo a 1000-fold selectivity over the other PPAR isotypes. 72 The PPARβ/δ gene is conserved between species, and there are no studies of rare human genetic mutations; however, PPARβ/δ polymorphism (e.g., rs2016520) is associated with increased LDL-c and reduced HDL-c concentrations, suggesting a role for this transcription factor in human cholesterol metabolism. 73 In addition, the relationship between PPARβ/δ polymorphism rs2016520 and the risk of showing three or more components of the MS is influenced by dietary habits. 74 Finally, interaction between PPARβ/δ single polymorphism and fasting plasma glucose levels and body mass index has been shown as well. 75 The role of PPARβ/δ in adiposity, skeletal muscle physiology, and lipoprotein regulation identified this NR as promising candidate for therapeutic intervention in MS ( Figure 2 ).
PPARβ/δ in Adipose Tissue
PPARβ/δ is expressed both in white adipose tissue (WAT) and BAT where it controls thermogenesis, FA . Effects of PPARβ/δ activation in tissues involved in metabolic homeostasis (right): in adipose tissue and muscle, PPARβ/δ induces fatty acid (FA) transport and oxidation, mitochondrial activity, and thermogenesis, thus increasing energy expenditure. In muscle, PPARβ/δ activation ameliorates the endurance capacity. In the liver, PPARβ/δ inhibits glucose output, thereby contributing to the peripheral glucose homeostasis. PPARβ/δ also induces increased serum high-density lipoprotein (HDL) levels, leading to enhanced reverse cholesterol transport (RCT), and reduced inflammation in the macrophages. These effects could further promote a PPARβ/δ-mediated cardiovascular prevention. transport, and oxidation and uncoupling of oxidative phosphorylation through activation of its target genes such as long-chain acyl-CoA dehydrogenase, CPT-1, ACOX-1, long-chain acyl-CoA-synthetase, and uncoupling protein-1 (UCP-1). 67, 76, 77 In rodents, PPARβ/δ adipose tissue-specific over-expression protected from diet-induced obesity, triglyceride accumulation in adipocytes, hypertriglyceridemia, and hepatic steatosis. 76 Administration of PPARβ/δ agonist GW501516 was able to mimic the effects of a constitutively active PPARβ/δ transgene in obese murine models but not in rhesus monkeys, 78 leaving unanswered the question whether PPARβ/δ fat-specific activation may have a metabolic relevance on the whole-body homeostasis.
PPARβ/δ in Muscle
Skeletal muscle is a key metabolic tissue accounting for approximately 80% of insulin-stimulated glucose uptake and, compared with liver and adipose tissue, is subjected to an almost complete unidirectional flux of FA with all imported FA oxidized rather than stored and/or exported. Both obesity and insulin resistance are linked to a decrease in the proportion of oxidative slow twitch (type 1) fibers in skeletal muscle. 79, 80 PPAR β/δ expression in skeletal muscle is 10-50 fold higher compared with that of PPARα or PPARγ and has been exclusively found in type 1 fibers that mainly use mitochondrial oxidative metabolism for energy production. 81, 82 PPARβ/δ skeletal muscle-specific deletion was found associated with weight gain, insulin resistance, and reduced FA oxidation. 83 Conversely, muscle-specific overexpression protected mice from diet-induced obesity 81 and was accompanied by muscle fiber type remodeling that ameliorated insulin sensitization. Of note, the therapeutic potential of a reprogramming of muscle endurance by targeting the AMPK-PPARδ signaling axis via orally active PPARδ agonists (GW501516) has been recently reported. This approach may hold promise in regard to the management of clinical conditions where exercise is recommended, such as obesity and MS. 84
PPARβ/δ and Lipoprotein Metabolism
Both animal and human studies have provided compelling evidence of a beneficial role of PPARβ/δ on lipoprotein metabolism. In obese as well as in hyper-cholesterolemic mouse models, PPARβ/δ agonist GW501516 increased HDL-c concentrations up to 50% along with a reduction of small dense LDL levels. [85] [86] [87] Obese rhesus monkeys have been used as model of human obesity and metabolic disorders and used in studies aimed to assess PPARβ/δ benefit on HDL metabolism. 78, 88 PPARβ/δ agonist GW501516 given as single daily dose, 88 or twice a day, 78 raised HDL-c levels up to 43 or 79%, respectively; lowered LDL-c; and increased apoAI and apoAII levels and HDL particle size. PPARs activate human apoAI gene via a positive PPRE located in the apoAI promoter A site; whereas a three nucleotide difference makes the positive PPRE nonfunctional in rodents, suggesting that primates, but not mice, are a good model for future investigations on the PPAR β/δ benefit on HDLc and the RCT. 88, 89 Although in some pilot studies in both normo-lipidemic and moderately obese subjects GW501516 treatment promoted a substantial increase in HDL-c, 90,91 the physiological relevance of PPAR β/δ-mediated HDL-raising effect remains still elusive in humans. Future insights may come from newer agonists, such as KD-3010 and MBX-8025, currently in the preclinical phases of research. 92
PPARγ
First cloned in 1994, 93 PPARγ was later identified as the receptor for the TDZ class of insulin-sensitizing drugs in 1995. 94 The PPARγ gene is transcribed into three splice variants (PPARγ 1, 2, and 3). PPARγ 1 and 3 transcripts give rise to PPARγ 1 protein that is highly produced in WAT, immune cells (macrophages and monocytes), intestine (colon), liver, and kidney, whereas the PPARγ 2 transcript encodes for a protein exclusively expressed in WAT and BAT. Monounsaturated and polyunsaturated FA, eicosanoid FA-derivatives [13-hydroxyoctadecanoic acid (13-HODE) and 9-HODE; mainly found in oxidized LDL] and prostanoids, such as 15-deoxy-12,14 -prostaglandin J 2 (15d-PGJ2) bind to PPARγ with micromolar range affinity, as reported in radioligand binding assays. 95, 96 The most highly studied of the PPARγ ligands are the TDZs, pioglitazone, and rosiglitazone, which have been approved for clinical use in type 2 diabetes since 1997 in US. (the physiological role of PPARγ activation is summarized in Figure 3 ).
PPARγ in Adipose Tissue
In vitro and in vivo studies have shown that PPARγ is the prime regulator of adipocyte differentiation. 97, 98 PPARγ -null fibroblasts and embryonic stem cells are differentiation-incompetent in vitro 99 and germ-line deletion of PPARγ , as well as PPARγ hypomorphic mice demonstrate the essential requirement for this transcription factor in the formation of adipose tissue in vivo. 100 Naturally occurring PPARγ mutations in humans support the key role of this NR in adipose tissue development and distribution. Patients harboring dominant-negative mutations in PPARγ gene exhibit familial partial lipidystrophy type 3 (FPLD3), concomitant with severe insulin resistance, dyslipidemia (elevated serum TGs and low HDL-c), and early onset . Effects of PPARγ activation in tissues involved in metabolic homeostasis (right): PPARγ activation improves glucose metabolism, inducing insulin sensitivity (in the liver, skeletal muscle, and adipose tissue), increasing glucose uptake from the muscle and reducing hepatic gluconeogenesis. In the adipose tissue, PPARγ also induces fatty acid (FA) uptake, adipogenesis, increased fat storage, and a better lipid repartition into adipocytes, leading to the formation of small, newly formed, and active adipocytes. Nevertheless, PPARγ increases the production of adiponectin from adipocytes, which is negatively correlated to metabolic unbalances and MS. In macrophages, PPARγ also induces an increased M2/M1 ratio (thus inhibiting inflammation) and contributes to an enhanced uptake of oxidized low-density lipoprotein (LDL). In addition, PPARγ regulates the transcription of the liver X receptor (LXR), lipoprotein lipase (LPL), and apolipoprotein E (apoE), further preventing atherosclerosis.
hypertension. [101] [102] [103] Common (e.g., PPARγ Pro12Ala polymorphism) and rare (loss-of-function mutations) variants in the gene encoding PPARγ provide additional genetic evidence of the central role of PPARγ in the MS. [104] [105] [106] [107] The finding that TDZs act as high affinity PPARγ agonists validated the efficacy of PPARγ modulation in the management of MS. 108 The TDZs are able to improve insulin sensitivity through increased lipid uptake and storage, decreased serum FFA and TG, reduced hepatic gluconeogenesis, increased peripheral glucose absorption and enhanced energy expenditure. 108 Studies in vivo had shown that WAT is the primary tissue responsible for the therapeutic effects of TDZs since mice lacking adipose tissue are refractory to the TDZ glucose-lowering effect. Additionally, PPARγ adipose-specific knockout mice are insulin-resistant and unresponsive to TDZs. [109] [110] [111] PPARγ activation in adipocytes stimulates a wide array of genes involved in FA uptake and storage including LPL, FATP-1, FA binding protein-4 (FABP-4), acyl-CoA synthase (ACS), perilipin, cell death-inducing DNA fragmentation factor subunit alpha (DFFA)-like effector A (CIDEA), CD36, and phosphoenolpyruvate-carboxykinase (PEPCK). [112] [113] [114] [115] [116] Adipocyte PPARγ activation leads to a lipid repartitioning from liver and skeletal muscle into fat, thus, reducing the circulating levels of FFA and eliminating the detrimental effects of lipid loading on insulin signaling (the so-called 'lipid steal phenomenon'). 117 PPARγ activation promotes a fat redistribution with an expansion of adiposity in the subcutaneous adipose tissue at the expense of visceral fat, 118,119 contributing to the weight gain observed in patients treated with TDZs compared with those receiving sulphonylurea. 120 In addition, PPARγ activation in adipose tissue enhances the production of adiponectin, 121 promoting FFA oxidation and insulin sensitivity via stimulation of AMP-activated proteinkinase in skeletal muscle and through inhibition of PEPCK in the liver.
PPARγ and Inflammation
Many lines of evidence support the link between hepatic inflammation and insulin resistance 122 and a family of suppressors of cytokine signaling (SOCS) has been shown to be involved in both inflammation and insulin resistance. Chronic PPARγ activation by pioglitazone in high-cholesterol fructose diet-fed rats improved insulin sensitivity by decreasing the hepatic expression of SOCS3, tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6). 123 Along with the aforementioned effects in the liver and skeletal muscle, PPARγ activation enhances glucose transporter member 2 (GLUT2) expression in pancreatic β-cells, leading to an augmented insulin secretion. [124] [125] [126] Obesity and insulin resistance, key features of the MS, have been consistently associated with a state of lowgrade inflammation which is caused likely by both adipocyte hypertrophy and macrophage infiltration into adipose tissue. 127 A polarization of adiposeresident macrophages from M2 (alternatively activated phenotype, less inflammatory) toward an M1 phenotype, characterized by enhanced secretion of pro-inflammatory mediators (TNF-α, IL-6) during diet-induced obesity, has been reported. 128 PPARγ is highly expressed in activated macrophages and is markedly induced upon IL-4 stimulation. 129, 130 Odegaard et al. elegantly showed that macrophage PPARγ is required for maturation of alternatively activated macrophages and PPARγ disruption in myeloid cells impairs the alternative macrophage activation, predisposing mice to development of high fat diet-induced obesity, insulin resistance, glucose intolerance, and muscle mitochondria dysfunction. 131 A short-term treatment with the PPARγ agonist rosiglitazone promoted infiltration of M2 macrophages into adipose tissue in high fat-fed mice. 132 The inability to undergo differentiation into M2 phenotype reported, when macrophage PPARγ was genetically disrupted, was found not only in high fat diet-fed animals but also in normal low fat diet-fed animals. 133 This finding indicates that macrophage PPARγ expression might be necessary to maintain an anti-inflammatory M2 phenotype and important for the achievement of the full insulin-sensitizing effects of TDZ. 134 The intriguing link between insulin sensitivity, macrophage PPARγ , and adipose tissue has been seen in humans as well. TDZ treatment improved insulin sensitivity and was associated to a marked reduction of adipose tissue CD68, monocyte chemoattractant protein-1 (MCP-1) mRNA abundance, and circulating TNF-α levels. 135
'Janus-face' of PPARγ Activation
Although extensively used in type 2 diabetes patients, TDZs are not completely devoid of side effects such as weight gain (∼2-3 kg per 1% glycosylated hemoglobin that is lowered), anemia, pulmonary edema, congestive cardiac failure, and increased risk of myocardial infarction 120 ; these outcomes will further limit the clinical usefulness of these drugs. To bypass the problem, it will be necessary to dissect the relative contributions of adipose versus non-adipose (macrophage, muscle, and liver) PPARγ activation to the systemic insulin sensitization; for this purpose, conditional PPARγ knockout mice have been used. 110, 133, 136, 137 Unfortunately, these studies could neither address the molecular basis for PPARγ action in different cell types, nor how TDZs can increase the ability of target cells to sense insulin. In addition, these studies did not circumvent all the complications caused by the loss-of-function of adipose PPARγ , such as the rebounded increase of PPARγ expression in liver and muscle. 109, 138 Recent studies addressed some of the aforementioned gaps in our knowledge of PPARγ biology and physiology. [139] [140] [141] Selective PPARγ activation in adipocytes, but not in macrophages, is sufficient for whole-body insulin sensitization equivalent to systemic TDZ treatment in mice. These data offer an 'adipocentric' model, where fat is not only a contributor, but a central player in insulin sensitization, 140 providing evidence for the need of cell-restricted PPAR modulators. Intriguingly, selective PPARγ modulators (SPARMs) can improve insulin sensitivity without causing weight gain. [142] [143] [144] The recent work by Lefterova et al. provides new evidence for how cell-type-specific gene expression may be achieved by a single NR. 139 Future efforts need to be directed toward the development of tissue-specific PPARγ agonists that can retain insulin-sensitizing properties without activating de novo adipogenesis and the consequent increased subcutaneous adiposity. In this regard, partial PPARγ /α agonists such as TDZ18 or small molecules such as harmine may hold this promise in a near future. 112, 145 
LIVER X RECEPTORS
First identified in 1994 by screening a rat liver cDNA library, LXRs were originally classified 'orphans', as their natural ligands were unknown. 146, 147 Subsequently 'adopted', when oxidized cholesterol derivatives, referred to as oxysterols, were shown to be endogenous ligands, 147, 148 LXRs have emerged as keystones in lipid, carbohydrate, and inflammatory homeostasis. [148] [149] [150] [151] In mammals, two LXR isoforms (LXRα and LXRβ) exist and both are highly expressed in the liver and the intestine, where their physiological roles have been best elucidated. 152 LXRα (NR1H3) is also expressed in WAT, macrophages, kidney, adrenal glands, lung, and spleen, whereas LXRβ (NR1H2) is ubiquitously expressed. LXRα and LXRβ not only exert overlapping but also separate metabolic functions, with the former being required for the control of hepatic cholesterol metabolism and the latter being the major regulator of glucose homeostasis and energy utilization in both muscle and WAT (Figure 4 ). 153 LXRs bind to cognate LXR-responsive elements (LXREs), consisting of DRs of the core sequence AGGTCA separated by four nucleotides (DR-4) 9,154 and to corepressors, such as silencing mediator of retinoic acid and thyroid hormone receptor 155 and NR corepressor (N-CoR). 156 As both LXRs form permissive heterodimers with the RXR, the complex can be activated either by oxysterols or retinoids. The binding of ligands results in conformational changes, allowing the interaction of the LXR-RXR complex with coactivators leading either to the transcription of target genes or the trans-repression of other genes not containing LXREs. 157, 158 LXR natural ligands include 22(R)-, 24(S)-, 27-, and 24(S),25-hydroxy cholesterol at concentrations within the physiological range while synthetic LXR ligands (T0 901317, GW3965) show EC50 values for both isoforms in the low nanomolar range. 147, 159 
LXR and Cholesterol Homeostasis
Liver X receptors function as whole-body 'cholesterol sensors' and most of their target genes in liver, intestine, and macrophages play a crucial role in the maintenance of cholesterol homeostasis and atherosclerosis. LXR is expressed in macrophages, being positively regulated by PPARγ , suggesting a link between the macrophage ability to remove cholesterol and the uptake of oxidized LDL. 9 LXRα may also induce its own transcript via an auto-regulatory loop in human but not in murine macrophages. 160, 161 The identification of the role of LXR in cholesterol efflux from macrophages via ABCA1 and ABCG1 upregulation, 162 and in the removal of excess cholesterol from peripheral tissues via RCT, pointed to a possible anti-atherosclerotic effect of LXR activation. 151, [162] [163] [164] [165] [166] [167] ABCA1 and ABCG1 mediate cholesterol and PL efflux from macrophages to lipid-poor lipoproteins and mature HDL, respectively, leading to the formation of the lipid-enriched HDL (i.e., HDL-2 and HDL-3 particles). 168 ABCA1 mutations cause the Tangier disease, a rare genetic disorder characterized by the absence of HDL in plasma, the accumulation of cholesterol in macrophages and an increased incidence of CVD. [169] [170] [171] [172] LXR activation cannot stimulate cholesterol efflux in fibroblasts from Tangier disease patients, demonstrating that ABCA1 is essential for the efflux pathway mediated by LXR. 166 Additionally, the activation of both LXR isoforms regulates apolipoprotein E (apoE) expression, both in the liver and macrophages. On the other hand, bone marrow transplantation from LXR-null mice into apoE-null mice results in a massive aortic lipid deposition. 150, 173 ApoE is an extracellular cholesterol acceptor required for the hepatic uptake of chylomicron remnants, VLDL and HDL, and serves as extracellular acceptor for ABCA1-mediated cholesterol efflux. 150 The increase in HDL concentration found upon LXR activation is the result of a coordinate regulation of a series of proteins involved in HDL formation and lipoprotein remodeling, such as LPL, PL transfer protein (PLTP) and CETP, which all are LXR target genes. 150, 152, [173] [174] [175] Macrophage LXR has been reported to be crucial for protection from atherosclerosis. 163 LXR activation results in NF-κB signaling suppression, [176] [177] [178] and ultimately to the repression of inflammatory genes [inducible nitric oxide synthase (iNOS), cycloxygenase 2 (COX-2), IL-6 and IL-1β, and matrix metallo-peptidase 9 (MMP-9), tissue factor, and osteopontin], and chemokines (MCP-1 and MCP-3). [176] [177] [178] [179] These are believed to be additional players in atherogenesis and CVD. 165 In the intestine, LXRs inhibit cholesterol absorption due to a reduced Niemann-Pick C1 like 1 gene expression, 180 and promote both sterol excretion into feces via apical ABC transporter ABCG5 and ABCG8 stimulation, and increase in HDL-c levels, leading to reduced lipid deposition and atherosclerosis development. [181] [182] [183] Conversely, mutations in ABCG5/G8 are associated with β-sitosterolemia, which is characterized by increased sterol absorption and early onset atherosclerosis. [183] [184] [185] Hepatic LXR activation induces ABCA1, 151,162 ABCG1, 168 ABCG5, and ABCG8 thus enhancing biliary cholesterol secretion. [186] [187] [188] Accordingly, LXRα-null mice accumulate cholesterol esters in the liver and develop hepatomegaly when fed a cholesterol-enriched diet. 189, 190 In rodent, but not in human liver, LXRα also induces the expression of cytochrome P450 7 α-hydroxylase (CYP7A1), the rate-limiting enzyme for cholesterol conversion to BAs. 191, 192 Additionally, LXRs mediate an enhanced transcription of the E3ubiquitin Inducible Degrader of the LDLR (Idol) 1, a protein able to induce LDL receptor (LDLR) degradation and that of other LDLR family members, such as the VLDL receptor (VLDLR) and apoE receptor 2 (ApoER2), 193, 194 thereby further preventing hepatic lipid accumulation.
LXR and Glucose Homeostasis
The close interplay of lipid and carbohydrate metabolism as well as the identification of LXR as mediators of insulin action in the liver suggested a possible role of LXR in glucose homeostasis. Administration of LXR agonists to obese, insulin-resistant mice inhibited hepatic gluconeogenesis via a decreased expression of PEPCK, fructose-1,6-bisphosphatase (FBP-ase) and glucose-6-phosphatase (G6P), improving both glucose tolerance and insulin sensitivity. 195, 196 Nevertheless, both hepatic gluco-kinase and insulin-dependent glucose transporter (GLUT4) are direct targets of LXRs in adipose tissue, suggesting that an increased glucose uptake and catabolism in this tissue could also contribute to the improved insulin sensitivity in animals receiving LXR agonists. 195, 196 LXRβ, and to a lesser extent LXRα, are expressed in both human and murine pancreatic islet cells where they enhance glucose-dependent insulin secretion, 197 an effect that is impaired in LXRβ knockout mice. 198 Collectively, the ability of LXRs to modulate glucose homeostasis results from a downregulation of hepatic gluconeogenesis, an increased insulin-stimulated glucose uptake from skeletal muscle and adipose tissue and an enhanced insulin secretion from the pancreas.
LXR and FA Metabolism
LXRs also regulate hepatic FA metabolism, 151 as they enhance the expression of the master transcriptional regulator of FA and TG biosynthesis, sterol regulatory element binding protein-1c (SREBP-1c), 199 leading to increased levels of FA synthase, ACS, and stearoyl-CoA desaturase 1 (SCD1) and repression of hepatic apoAV. 149, 173, 200, 201 In addition, LXRs increase the expression of the glucose-sensitive transcription factor carbohydrate-responsive element binding protein (ChREBP). 202 By regulating both SREBP-1c and ChREBP, LXRs contribute to the induction of FA synthesis in response to glucose and insulin. 202, 203 Accordingly, the LXR-driven fatty liver phenotype is completely abolished in LXR-null mice. 151 The hepatic steatosis developed upon LXR activation, along with the observation that LXR agonist administration to a diabetic mouse model (db/db) resulted in a severe lipogenic disease, 149, 204 are the major pitfalls of pharmacological LXR activation. Several strategies have been proposed to avoid both the lipogenic effects and the LXR-mediated induction of CETP (correlating with increased LDL cholesterol levels) in humans but not in mice, which do not express CETP. 205 The clinical relevance of LXR agonists for treatment of CVD remains to be established, as a direct extrapolation of evidences from the murine model to humans are limited by species-specific differences in lipoprotein metabolism and target genes. 163, 206, 207 Human studies addressing the cardioprotective potential of LXR activation are needed.
FARNESOID X RECEPTOR
The FXR (NR1H4), cloned in 1995, 208 was initially believed sensing farnesol and juvenile hormone III. 209 In 1999, cholic acid (CA) and chenodeoxycholic acid (CDCA) were shown to activate FXRα. 9, [210] [211] [212] As the conversion of cholesterol to BAs is the major pathway for elimination of cholesterol, 191 FXR regulates both cholesterol and BA homeostasis. Bile acids are central mediators of the digestion and absorption of lipids, cholesterol, and lipid-soluble vitamins, and prevent the precipitation of cholesterol crystals in bile. 213, 214 As 95% of BAs are reabsorbed by enterocytes and recirculate, and increased BA levels can be toxic, a feedback modulation of BA synthesis and absorption is essential for cholesterol and BA depletion. 191 Two FXR genes have been identified: FXRα and FXRβ. FXRβ is believed to be a lanosterol sensor in rodents, rabbits, and dogs, but constitutes a pseudogene in humans and primates. 215 FXRα is expressed in liver, intestine, kidney, adrenal gland, heart, and WAT, 209, 216, 217 and encodes four FXRα isoforms (FXRα1, FXRα2, FXRα3, and FXRα4), resulting from differential use of two promoters and alternative splicing. 216, 217 FXR can bind to and activate or repress different FXR response elements (FXREs), as a classical heterodimer with RXR or as a monomer, 215, 218 interacting with different coactivator complexes. [219] [220] [221] [222] [223] [224] BAs can activate the transcription of FXR target genes at physiological concentrations acting as hormones. [210] [211] [212] Other FXRα ligands include natural agonists (Cafestol), semi-synthetic agonists [6α-ethyl-chenodeoxycholic acid (6α-ECDCA)], synthetic agonists (GW9047, GW4064, fexarine and fexaramine, 4-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8tetramethyl-2-naphthalenyl)-1-propenyl]benzoic acid (TTNPB), AGN29, and AGN31), natural antagonists (guggulsterone), and synthetic antagonists (AGN34). Some of these compounds act as partial antagonists or gene-selective agonists/antagonists, depending on the target gene. [225] [226] [227] [228] [229] [230] [231] [232] 
FXR and Bile Acid Homeostasis
FXR controls the enterohepatic circulation of BAs by regulating the efflux of BAs from the liver, their intestinal absorption, and hepatic reuptake. 191 FXR regulates genes involved in BA transport, conjugation, and detoxification, as well as in BA (bile salt export pump and multidrug resistance protein 2) and PL (h-MDR3 or m-MDR2) biliary secretion. 162, 213, 214, [233] [234] [235] [236] [237] [238] [239] [240] In the liver, FXR represses the transcription of the gene encoding CYP7A1, through a bipartite mechanism involving coordinated actions in the intestine and the liver. In ileum, FXR induces the expression of fibroblast growth factor 15 (FGF15), 241,242 a hormone that plays an overarching role in regulating BA homeostasis. In liver, FXR induces the expression of small heterodimer partner (SHP), 243, 244 an orphan NR that binds the CYP7A1 promoter through interactions with another NR, liver receptor homolog-1. 189, [243] [244] [245] [246] Induction of both FGF15 and SHP is required for the FXR-mediated repression of CYP7A1 and BA synthesis. FXR also represses the hepatic expression of sterol 12α-hydroxylase (CYP8B1), an enzyme controlling the ratio of the primary BA cholate and β-muricholate in mice. 247
FXR and Lipoprotein Homeostasis
Both FXR synthetic agonist and CDCA decrease serum total cholesterol levels (due to reduced cholesterol absorption and to a reduction in circulating HDL-c), reduce the expression of apoAI, and increase PLTP-mediated HDL remodeling. 218, [248] [249] [250] [251] [252] [253] [254] Additionally, CDCA increases the expression of LDLR, leading to decreased LDL-C plasma levels. 255 In turn, the inhibition of CYP7A1 results in increased hepatocyte cholesterol and oxysterols levels, activating LXR with subsequent ubiquitation of LDLR. 149, 194 In mice, FXR activation has been related to a net reduction in plasma LDL-C levels, 249, 256, 257 and these effects can be seen also in humans, but only upon long-term CDCA treatment. 258, 259 On the other hand, the FXR antagonist guggulsterone has been shown to reduce total cholesterol and increase HDL serum levels. 227 The ability of BA to impact lipid metabolism has been first described in cholesterol gallstone patients receiving CDCA. 260 CDCA, but not ursodeoxycholic acid, that does not activate FXR, showed the ability of lowering plasma TG in patients both with cholesterol gallstones and hypertriglyceridemia. 253, [260] [261] [262] In mice, FXR activation decreases plasma FFA and TG levels via SHP-mediated suppression of SREBP-1c and its target genes, and reduces VLDL-TG secretion, along with a increased TG clearance. [247] [248] [249] 257, [263] [264] [265] [266] [267] [268] [269] Additionally, FXR can increase FA oxidation and fat utilization via enhanced PPARα expression. 270, 271 Conversely, FXR deficiency in rodents is associated with a massive cholesterol and TG deposition in the liver as well as elevated circulating FFA levels, 247, 257, 268, 269 whereas in dyslipidemic patients BA-sequestrating agent treatment results in increased plasma TG and VLDL levels. 252, 272, 273 
FXR and Glucose Homeostasis
The link between FXR and glucose metabolism emerged when altered BA profile was found to be associated with type 2 diabetes in both humans and animal models, [274] [275] [276] suggesting that insulin may affect BA metabolism. At transcriptional level, FXR is positively regulated upon fasting and by glucose administration, although being negatively regulated by insulin and upon refeeding condition. 277, 278 In fasted mice, BAs prevent gluconeogenesis, determining hypoglycemia. [277] [278] [279] [280] [281] Wild-type, obese, and insulinresistant mice expressing an activated form of FXR, as well as those treated with FXR agonists (BAs or synthetic agonist), show reduced plasma glucose, hypoinsulinemia and improved insulin sensitivity, paralleled by raised hepatic glycogen levels, and increased hepatic signaling downstream of the insulin receptor. 256, 257, 268 BA or synthetic FXR agonist administration induces glycogen synthase kinase expression (promoting glycogen synthesis), and decreased gluconeogenesis by repressing PEPCK, G6P, and FBP-ase, via an FXR/SHP-dependent mechanism [involving hepatic nuclear factor 4α (HNF-4α), proliferator-activated receptor-gamma coactivator 1α (PGC-1α), and the Forkhead Transcription Factor]. 279, 281, 282 This effect of BAs in physiological conditions could be mediated additionally by an FXR-independent mechanism, involving HNF-4α. 281 Paradoxically, FXR agonists, although being able to stimulate glucose output from primary hepatocytes, do not alter plasma glucose levels in fed wild-type mice. 280 All FXR effects seen in fasting mice upon FXR agonists are abrogated in FXR knockout mice, showing a lipo-atrophic phenotype, impaired glucose tolerance, and insulin resistance. 256, 257, 268 Loss of FXR disrupts glucose homeostasis and impairs insulin signaling in muscle and WAT where FXR is completely absent (muscle) or expressed at undetectable level (WAT) in normal animals. 256, 268 These results could be related to unbalances in the FGF15/19 modulation of insulin signaling, 283, 284 or to other changes in insulin or lipid signaling leading to elevated FFA and TG production, and finally to increased circulating FFA levels. 249, 256, 257, 268 On the other hand, plasma glucose levels have been reported as unchanged, 257 increased 268 or reduced 256 in FXR knockout mice suggesting that other factors still need to be elucidated. These results seem to be discordant, probably due to differences in the genetic backgrounds of the mice or to specific experimental procedures. As FXR modulates the gluconeogenic program during the fasting period, FXR-knockout mice show an altered regulation during the shift from a glucose output regimen to a glucose utilization one. 277 Nevertheless, some of the BA beneficial effects on the modulation of energy expenditure and metabolism can also be driven through an FXR-independent pathway. CA-treated animals are protected from diet-induced obesity through the activation of G-protein-coupled BA receptor 1 (Gpbar1, also known as TGR5) and the induction of UCP-1 in BAT. 285 In this respect, the development of dual FXR and TGR5 ligands may hold promise in the management of metabolic disorders and obesity. Additionally, an increasing body of evidence supports a role for gut microbiota abnormalities in the perpetuation of the main features of MS, such as low grade of inflammation and insulin resistance. 286, 287 Inagaki et al. found that FXR activation increases the expression of target genes exhibiting intestinal antibacterial properties (i.e., iNOS and IL-18), leading to a negative modulation of gut microflora. 288 Further investigation on the FXR-mediated modification of gut microbiota in a setting of MS and insulin resistance may disclose unknown mechanisms by which BA contribute to the whole-body energy homeostasis.
FXR and the Etiology of Atherosclerosis
FXR has also been implicated in the etiology of atherosclerosis not only due to the metabolic reasons we just discussed, but also via the modulation of inflammation. 289, 290 Indeed, FXR is expressed in endothelium, 291 vascular smooth muscle cells, 292 and atherosclerotic lesions, but not in the macrophages. 269 The roles at this level are under debate, as BAs administration has been linked to responses that could be both beneficial, 291 or not, 293 for atherosclerosis. However, FXR knockout mice fed high-fat or highcholesterol diet show a pro-atherogenic metabolic profile, which is not paralleled by an enhanced susceptibility to atherosclerosis. 269, 294 As the murine model does not develop spontaneously atherosclerosis, FXR knockout mice have been crossed with genetic models of atherosclerosis. Unfortunately, the effects of loss of FXR in models of atherosclerosis were not disclosed, as these models showed contrasting and case-specific outcomes depending on the genetic background of the mice. 269, 294, 295 Although FXR activation shows positive effects on lipid and glucose metabolism ( Figure 5 ), pointing on the possibility of FXR as a possible target for MS treatment, these positive effects are not paralleled by sufficient data on the modulation of the atherosclerotic phenomenon by FXR agonists. The exact role of FXR on the atherogenic process is still poorly understood and should be clarified by further investigations before going into clinical confirmation in humans.
CONCLUSIONS
The rapid escalation of the incidence of obesity and MS calls for a careful appraisal of the effectiveness of the current therapies. Among the several therapeutic approaches used over the last decades, only lifestyle modifications and metformin are considered truly effective in the MS clinical picture. NRs, master transcriptional regulators of the metabolic homeostasis, are ideal targets for the pharmacological modulation of metabolic networks. Fibrates (PPARα agonists) and TZDs (PPARγ agonists) are well-established therapies for hypertriglyceridemia and diabetes, but their long-term benefits are still under discussion. Another promising option for hypertriglyceridemia could be the activation of FXR. In the treatment of MSassociated dyslipidemia, LXR ligands are also promising, as LXR activation is able to lower total cholesterol levels and increase nascent HDL levels, thus inducing RCT. A tissue-selective activation may prevent the 
